Mesoblast (MEOBF) Retained Earnings (2014 - 2026)
Mesoblast's (MEOBF) quarterly Retained Earnings came in at -$1.1 billion in Q2 2026, down 5.69% year-over-year from -$1.1 billion in Q2 2025, and down 1.65% quarter-over-quarter from -$1.1 billion in Q4 2025.
Analysis
Mesoblast (MEOBF) Retained Earnings (2014 - 2026) Analysis & Trends
Mesoblast has disclosed Retained Earnings across 13 years of filings, most recently posting -$1.1 billion for Q2 2026.
- In Q2 2026, Retained Earnings fell 5.69% year-over-year to -$1.1 billion; the TTM figure through Jun 2026 stood at -$1.1 billion (down 5.69% YoY), while the FY2026 annual figure was -$1.1 billion, down 5.69% from the prior year.
- Retained Earnings came in at -$1.1 billion for Q2 2026 at Mesoblast, down from -$1.1 billion in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$717.5 million in Q1 2022 to a low of -$1.1 billion in Q2 2026.
- Average Retained Earnings over 5 years is -$871.8 million, with a median of -$837.1 million recorded in 2023.
- Year-over-year, Retained Earnings slipped 14.7% in 2022 and fell 5.69% in 2026.
- Over 5 years, Retained Earnings stood at -$780.3 million in 2022, then dropped by 9.36% to -$853.3 million in 2023, then dropped by 12.11% to -$956.7 million in 2024, then declined by 9.86% to -$1.1 billion in 2025, then decreased by 1.65% to -$1.1 billion in 2026.
- Per Business Quant data, the three most recent Retained Earnings figures were -$1.1 billion in Q2 2026, -$1.1 billion in Q4 2025, and -$1.0 billion in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | 1.23 Bn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | -2.16 Bn |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | 3.62 Bn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | 1.23 Bn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | 1.84 Bn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | 2.93 Bn |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 2.37 Bn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | -4.55 Bn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | -380.40 Mn |
| 10 | Mesoblast | 246.02 Mn | 143.11 Mn | - | -1.07 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.07 Bn |
| Dec 31, 2025 | -1.05 Bn |
| Jun 30, 2025 | -1.01 Bn |
| Dec 31, 2024 | -956.70 Mn |
| Jun 30, 2024 | -908.76 Mn |
| Dec 31, 2023 | -853.34 Mn |
| Jun 30, 2023 | -820.81 Mn |
| Mar 31, 2023 | -798.89 Mn |
| Dec 31, 2022 | -780.29 Mn |
| Sep 30, 2022 | -755.80 Mn |
| Jun 30, 2022 | -738.92 Mn |
| Mar 31, 2022 | -717.46 Mn |
| Dec 31, 2021 | -696.16 Mn |
| Sep 30, 2021 | -670.21 Mn |
| Jun 30, 2021 | -647.57 Mn |
| Mar 31, 2021 | -625.51 Mn |
| Dec 31, 2020 | -598.99 Mn |
| Sep 30, 2020 | -573.30 Mn |
| Jun 30, 2020 | -548.76 Mn |
| Mar 31, 2020 | -516.15 Mn |